Tag Archives: nasal glucagon

Lilly Nasal Glucagon CHMP Opinion This Week (CHMP Agenda October 14-17)

The CHMP agenda for this week’s meeting (October 14-17) has been released, and it includes two notable items (Lilly nasal glucagon opinion and Toujeo age indication extension). Below, FENIX provides diabetes-related highlights and insights from the CHMP agenda.

This content is for Read Less members only.
Register

Already a member? Log in here

FENIX Analysis: Baqsimi, Lilly’s Novel Nasal Glucagon Hypo Rescue Product

Recently, Lilly’s novel nasal glucagon hypo rescue product, Baqsimi [BAK-see-mee], was approved by FDA. Below, FENIX provides an in-depth analysis of the Baqsimi label, pricing strategy, and potential market implications for other novel glucagon rescue products from Xeris, Zealand, and Mylan.

This content is for Read Less members only.
Register

Already a member? Log in here